No Data
innovative phar (00399.HK) mid-term attributable profit of approximately 0.102 billion Hong Kong dollars.
Grace 11th, innovative phar (00399.HK) announced that for the six months ended September 30, 2024, the group's revenue was approximately 3,000,000 Hong Kong dollars, a decrease of about 18.9% from the total revenue of approximately 3,700,000 Hong Kong dollars in the previous fiscal period. The decrease is mainly due to a decrease in business from the beauty equipment and product trading division during this fiscal period. During this fiscal period, the group recorded a profit attributable to owners of the company of approximately 101,700,000 Hong Kong dollars, compared to a profit of 193,700,000 Hong Kong dollars in the previous fiscal period. The profit for the two periods is attributed to the company.
INNOVATIVE PHAR: ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024
Innovative phar (00399.HK) will hold a board of directors meeting on November 29 to approve the interim performance.
According to a statement on November 14 by the innovative phar (00399.HK), the board of directors will hold a meeting on Friday, November 29, 2024, to consider and approve the consolidated interim results for the six months ended September 30, 2024, for the company and its subsidiaries.
INNOVATIVE PHAR: NOTIFICATION OF BOARD MEETING
Innovative Phar intends to acquire a majority stake in Niraxx. Inc.
Innovative Phar (00399) announced that on November 12, 2024, the company, as an investor, has entered into a memorandum of understanding with the target (Niraxx. Inc.), indicating its intention to invest in the majority equity of the target. It is reported that the target is a limited company registered in Delaware, usa, mainly engaged in (a) developing the ai-driven virtual health platform SyncWell; (b) developing the brain neural technology service platform DeepSynaps; (c) integrating optical biological regulation technology into sportswear; and (d) developing
Innovative Phar (00399.HK) plans to invest in the field of AI in medical care and other areas.
Grants 12th of November: innovative phar (00399.HK) announced that on 12th November 2024, as an investor, the company has entered into a memorandum of understanding with the symbol, indicating the company's intention to invest in the potential investment of the majority of the target's equity. The target is a limited liability company registered in Delaware, USA, mainly engaged in (a) developing the ai-driven virtual health platform SyncWell, using ai applications to integrate and analyze dispersed health data, providing users with personalized real-time advice; and (b) developing innovative brain nerve technology service platform.
Innovative Pharmaceutical Biotech (HKG:399) Is Posting Solid Earnings, But It Is Not All Good NewsNo Data
No Data
